[Immune responses induced by recombinant adenovirus Ad5F35-LMP2 in rhesus monkeys].
OBJECTIVE
To observe the specific cellular and humoral immune responses after immunization with recombinant adenovirus Ad5F35-LMP2 in rhesus monkeys.


METHODS
Sixteen rhesuses were immunized with Ad5F35-LMP2 through intra-muscular injection in three groups: high dosage group (1.5 x 10(10) TCID(50)/rhesus), medium dosage group (1.5 x 10(9)TCID(50)/rhesus), low dosage group (1.5 x 10(8)TCID50/rhesus) and the last group was control (PBS 4 ml/rhesus). They were totally immunized three times at intervals of one month. The EBV-LMP2 specific cellular immune responses were tested during the 0, 4, 8, 12 weeks by Elispot after immunization respectively. And the titers of anti-LMP2 antibody were tested by EIA at the same time.


RESULTS
EBV-LMP2 specific cellular and humoral immune responses which were induced by recombinant adenovirus Ad5F35-LMP2 can be found in all the three dosage groups. The potency of immune responses was related with the dosage of immunization. Higher dosage elicited more potent immune response.


CONCLUSIONS
The recombinant adenovirus Ad5F35-LMP2 could elicit LMP2 specific cellular and humoral immune responses in rhesus.
Mo
Wu-Ning
WN
First Affiliated Hospital, Guangxi Medical University, Nanning, China.
Zhou
Ling
L
Wu
Xiao-Bing
XB
Wang
Zhan
Z
Tang
An-Zhou
AZ
Huang
Guang-Wu
GW
Yu
Shuang-Qing
SQ
Wang
Qi
Q
Ye
Shu-Qing
SQ
Du
Hai-Jun
HJ
Zeng
Yi
Y
D000260:Adenoviruses, Human / Q000235:genetics*; D000818:Animals; D002454:Cell Differentiation; D004854:Herpesvirus 4, Human / Q000235:genetics; D007111:Immunity, Cellular / Q000276:immunology*; D007114:Immunization / Q000379:methods; D008253:Macaca mulatta; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology*; D014763:Viral Matrix Proteins / Q000235:genetics / Q000276:immunology*
C037662:EBV-associated membrane antigen, Epstein-Barr virus; D011993:Recombinant Fusion Proteins; D014763:Viral Matrix Proteins